Pfizer halts Phase III trial, withdraws Thelin

Pfizer ($PFE) announced that it is withdrawing pulmonary arterial hypertension drug Thelin (sitaxentan) after the company observed  life-threathening liver toxicity issues in subjects enrolled in a Phase III trial. "Given the availability of alternate treatments, Pfizer has concluded that the overall benefit of Thelin no longer outweighs the risk in the general population of PAH patients," the company explained in a statement. Thelin competes with Actelion's blockbuster drug Tracleer, which is approved in the U.S.

Pfizer acquired Thelin after its 2008 buyout of Encysive Pharmaceuticals. The drug was first submitted 2006, but the agency demanded another late-stage trial of the treatment to prove Thelin met efficacy standards. Encysive tried unsuccessfully to get the agency to change its mind without having to conduct another trial, but the FDA did not relent. However, a Phase III trial did get under way after Pfizer spent $195 million to acquire the company in 2008. Encysive was successful in gaining approval for Thelin in Europe, Australia and Canada. Pfizer's Phase III trial of the drug has been halted and the company is recommending that patients on the drug be switched to another treatment as soon as possible.

- check out Pfizer's release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.